Versant Capital Management »

Rapport Therapeutics shares owned by Versant Capital Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Versant Capital Management from 13F filings

Historical chart of Versant Capital Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Versant Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Versant Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $845 27 31.30

More positions owned by Versant Capital Management

Microsoft Stock (MSFT)
Avantis International Equity Etf Etf (AVDE)
Flexshares Tr Mornstar Upstr Etf (GUNR)
Dimensional U.s. Core Equity 2 Etf Etf (DFAC)
Avantis Emerging Markets Equity Etf Etf (AVEM)
Ishares S&p Global Energy Etf (IXC)
Vaneck Gold Miners Etf Etf (GDX)
Dimensional International Core Equity 2 Etf Etf (DFIC)
Apple Stock (AAPL)
Avago Technologies Stock (AVGO)
Nvidia Corp Stock (NVDA)
Ishares Gold Trust Micro Etf Of Benef Interest Etf (IAUM)
Vanguard Total Stk Mkt Etf (VTI)
State Street Spdr S&p Global Natural Resources Etf Etf (GNR)
Global X Fds Global X Ftse Greece 20 Etf Etf (GREK)

View all positions for Versant Capital Management

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
BlackRock
Sofinnova Ventures
Vanguard Group
Johnson & Johnson
Baker Bros. Advisors
Vestal Point Capital
Vanguard Capital Management
Polar Capital Holdings
Trv Gp Vi

View all funds holding Rapport Therapeutics